Metabolic syndrome in schizophrenia

Area of Science:

• Psychiatry and Metabolic Health
• Schizophrenia Research
• Pharmacological Interventions

Background:

• Metabolic syndrome (MetS) is a cluster of conditions that increase the risk of heart disease, stroke, and type 2 diabetes.
• Schizophrenia is a chronic mental disorder affecting how a person thinks, feels, and behaves.
• Patients with schizophrenia often exhibit a higher prevalence of MetS compared to the general population.

Purpose of the Study:

• To review existing data on the prevalence of metabolic syndrome (MetS) in individuals with schizophrenia.
• To identify correlates and risk factors associated with MetS in this patient population.
• To explore potential biological markers and future intervention targets for MetS in schizophrenia.

Main Methods:

• Systematic literature search of electronic databases including PubMed, ScienceDirect, and Google Scholar.
• Analysis of cross-sectional and longitudinal study data on MetS prevalence in schizophrenia patients.
• Review of demographic, clinical, and genetic factors associated with MetS.

Main Results:

• MetS prevalence in medicated schizophrenia patients ranges from 11% to 69%, and 4% to 26% in drug-naive patients.
• Longitudinal studies show prevalence increasing significantly with antipsychotic treatment, reaching up to 52.4% by 3 months.
• Risk increases with age; atypical antipsychotics like clozapine and olanzapine are associated with higher MetS risk.
• Preliminary evidence suggests links between MetS and adiponectin levels, hematological indices, and specific genes (MTHFR, ADRA1A).

Conclusions:

• Schizophrenia patients face a substantially elevated risk of metabolic syndrome compared to controls.
• Age and specific atypical antipsychotics are key risk factors requiring vigilant monitoring by psychiatrists.
• Further research into biological correlates may offer future preventive strategies for MetS in schizophrenia.